COMPANY
Natera
FDA-cleared device company Past trials only
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Scientist, IVD BioDevelopment | Austin, TX | Oct 22, 2026 | Oct 23, 2026 |
| Supervisor, Prior Authorizations | US Remote | Oct 22, 2026 | Oct 23, 2026 |
| IT Helpdesk Specialist 2 | San Carlos, CA | Oct 22, 2026 | Oct 23, 2026 |
| IT Helpdesk Specialist 2 | Austin, TX | Oct 22, 2026 | Oct 23, 2026 |
| Lab Assistant I | San Carlos, CA | Oct 22, 2026 | Oct 23, 2026 |
Trial and FDA signals
- Device approval + hiring FDA PMA device approval for Signatera CDx (P260004, May 15, 2026); since then posted 65 manufacturing/quality or commercial roles. FDA P260004 (May 15, 2026)
Evidence (1 event)
- May 15, 2026 · FDA P260004
openFDA device/pma: pma_number=P260004; supplement_number=(none); applicant='Natera, Inc.'; decision_code=APPR; decision_date=2026-05-15; trade_name='Signatera\x99 CDx'
- May 15, 2026 · FDA P260004
Timeline
- Trial start Not phased (device or behavioral study): A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumor source ↗
- Board tracked Radar started tracking this company’s job board (234 open jobs at last check). source ↗
- Trial start Not phased (device or behavioral study): Signatera Assessment in Early-Stage Endometrial Cancer source ↗
- Trial start Not phased (device or behavioral study): Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer source ↗
- Trial start —: Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC) source ↗
- Trial start —: Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) source ↗
- Trial start Not phased (device or behavioral study): Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT) source ↗
- Trial start Not phased (device or behavioral study): Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer source ↗
- Partnership Partnership / licensing announced Jan 7, 2026. Source: company's own press page. source ↗
- Partnership Partnership / licensing announced Dec 12, 2025. Source: company's own press page. source ↗
- Trial start —: Sample Collection for Ongoing Research and Product Evaluation Study source ↗
- Trial start —: Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC) source ↗
- Trial start Not phased (device or behavioral study): A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy source ↗
- Trial start —: Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection source ↗
- Trial start —: EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND) source ↗
- Trial start Not phased (device or behavioral study): Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation source ↗
- Trial start —: Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation source ↗
- Trial start —: LAMBDA 002 (Lung Registry) Study source ↗
- Trial start —: Prospera Test Evaluation in Cardiac Transplant (ProTECT) source ↗
- Trial start —: Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Management. source ↗
- Trial start —: Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies source ↗
- Trial start Not phased (device or behavioral study): Renasight Clinical Application, Review and Evaluation (RenaCARE) Study source ↗
- Trial start —: BESPOKE Study of ctDNA Guided Immunotherapy source ↗
- Trial start —: BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer source ↗
- Trial start —: The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive) source ↗
Upcoming milestones
- Oct 1, 2026 (ESTIMATED) · · The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive) · NCT04091984
- Oct 31, 2026 (ESTIMATED) · · Prospera Test Evaluation in Cardiac Transplant (ProTECT) · NCT05205551
- 2027-02 (ESTIMATED) · Not phased · A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy · NCT06414603
- 2027-04 (ESTIMATED) · · EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND) · NCT06808880
- Jul 10, 2027 (ESTIMATED) · · Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC) · NCT07046585
- 2027-12 (ESTIMATED) · Not phased · Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT) · NCT07718633
- 2028-09 (ESTIMATED) · Not phased · Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer · NCT07565857
- 2032-04 (ESTIMATED) · · Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) · NCT07750886
Open jobs 195
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Scientist, IVD BioDevelopment | Austin, TX | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Supervisor, Prior Authorizations | US Remote | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| IT Helpdesk Specialist 2 | San Carlos, CA | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| IT Helpdesk Specialist 2 | Austin, TX | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Lab Assistant I | San Carlos, CA | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Account Sales Representative (Orlando West) | Orlando, FL | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Account Sales Representative (Orlando West) | Orlando, FL | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| CQV Engineer | Austin, TX | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Associate CQV Engineer | Austin, TX | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Account Sales Representative | Modesto, CA; San Jose, CA | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Oncology Trial Navigator | US Remote | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Scientist R&D | San Carlos, CA | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Staff Scientist R&D | San Carlos, CA | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Senior Scientist R&D | San Carlos, CA | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Senior Lab Equipment Tech | Austin, TX | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Digital Product Manager, Tissue Acquisition Experience | US Remote | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Sr HR Business Partner | US Remote | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Associate Clinical Oncology Specialist | Shreveport, LA; Tyler, TX | Oct 20, 2026 | Oct 20, 2026 | Not stated |
| Associate Clinical Oncology Specialist | Dallas, TX | Oct 20, 2026 | Oct 20, 2026 | Not stated |
| Enterprise Strategic Accounts Manager | Chicago, IL; Madison, WI; Milwaukee, WI | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Clinical Oncology Specialist, Breast | Dallas, TX; Fort Worth, TX | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Clinical Oncology Specialist, Breast | Cincinnati, OH; Cleveland, OH; Lexington, KY; Louisville, KY | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Clinical Oncology Specialist, Breast | Philadelphia, PA; South Jersey | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Director of Bioinformatics and Machine Learning | San Carlos, CA | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| PSC Manager - Olympia, WA | US Remote | Oct 18, 2026 | Oct 19, 2026 | Not stated |
| Associate Clinical Oncology Specialist | Los Angeles, CA; Pasadena, CA | Oct 16, 2026 | Oct 17, 2026 | Not stated |
| Associate Clinical Oncology Specialist | San Jose, CA | Oct 16, 2026 | Oct 17, 2026 | Not stated |
| Rare Disease Specialist | Oakland, CA; San Francisco, CA | Oct 16, 2026 | Oct 17, 2026 | Not stated |
| Histotechnician II | San Carlos, CA | Oct 16, 2026 | Oct 17, 2026 | Not stated |
| Account Sales Representative | Lafayette, LA; Lake Charles, LA | Oct 16, 2026 | Oct 17, 2026 | Not stated |
| Medical Science Liaison - Rare Disease | US Remote | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Email Marketing Specialist-Temp | US Remote | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Principal AI Engineer | US Remote | Oct 15, 2026 | Oct 23, 2026 | Not stated |
| Data Privacy Manager | US Remote | Oct 14, 2026 | Oct 15, 2026 | Mid |
| Data Privacy Director | US Remote | Oct 14, 2026 | Oct 15, 2026 | Senior |
| Mobile Patient Services Specialist - San Antonio, TX | San Antonio, TX | Oct 14, 2026 | Oct 15, 2026 | Mid |
| Mobile Patient Services Specialist Lead - San Antonio, TX | San Antonio, TX | Oct 14, 2026 | Oct 15, 2026 | Senior |
| Clinical Oncology Specialist, GU | Pittsburgh, PA | Oct 14, 2026 | Oct 15, 2026 | Mid |
| Clinical Oncology Specialist, GU | Detroit, MI; Indianapolis, IN | Oct 14, 2026 | Oct 15, 2026 | Mid |
| Clinical Oncology Specialist, GU | Orlando, FL | Oct 14, 2026 | Oct 15, 2026 | Mid |
| Clinical Oncology Specialist, GU | Denver, CO; Phoenix, AZ | Oct 14, 2026 | Oct 15, 2026 | Mid |
| Staff Biostatistician (Clinical Validation) | San Carlos, CA | Oct 14, 2026 | Oct 15, 2026 | Senior |
| Staff Biostatistician (Clinical Validation) | US Remote | Oct 14, 2026 | Oct 15, 2026 | Senior |
| Director, ECD Development | San Carlos, CA | Oct 14, 2026 | Oct 15, 2026 | Senior |
| Senior Director, Development - ECD and MCED Products | San Carlos, CA | Oct 14, 2026 | Oct 15, 2026 | Senior |
| Clinical Oncology Specialist, H&N | Cleveland, OH | Oct 14, 2026 | Oct 15, 2026 | Mid |
| Clinical Oncology Specialist, GU | Washington D.C | Oct 14, 2026 | Oct 14, 2026 | Mid |
| Regional Director, GU Oncology Sales | East, US Region | Oct 14, 2026 | Oct 14, 2026 | Senior |
| Regional Director, GU Oncology Sales | West, US Region | Oct 14, 2026 | Oct 14, 2026 | Senior |
| Finance Functional Lead, Oracle Fusion Cloud | US Remote | Oct 13, 2026 | Oct 14, 2026 | Senior |
Funding
Clinical trials (lead sponsor) 36
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07214532 | Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer | Not phased (device or behavioral study) | Recruiting | May 8, 2026 | May 15, 2032 (estimated) |
| NCT05004337 | Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies | Not listed | Completed | Jul 22, 2021 | Nov 29, 2023 (actual) |
| NCT07763197 | Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC) | Not listed | Recruiting | Jul 27, 2026 | 2032-07 (estimated) |
| NCT07750886 | Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) | Not listed | Recruiting | Jul 27, 2026 | 2032-04 (estimated) |
| NCT07689812 | A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. | Not phased (device or behavioral study) | Not yet recruiting | 2026-12 | 2033-12 (estimated) |
| NCT07718633 | Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT) | Not phased (device or behavioral study) | Not yet recruiting | 2026-07 | 2027-12 (estimated) |
| NCT07339384 | Signatera Assessment in Early-Stage Endometrial Cancer | Not phased (device or behavioral study) | Not yet recruiting | 2026-10 | 2034-10 (estimated) |
| NCT07565857 | Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer | Not phased (device or behavioral study) | Not yet recruiting | 2026-09 | 2028-09 (estimated) |
| NCT06808880 | EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND) | Not listed | Recruiting | Jan 25, 2024 | 2027-04 (estimated) |
| NCT06414603 | A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy | Not phased (device or behavioral study) | Active, not recruiting | Jun 10, 2024 | 2027-02 (estimated) |
| NCT07318051 | Sample Collection for Ongoing Research and Product Evaluation Study | Not listed | Recruiting | Jul 21, 2025 | 2035-01 (estimated) |
| NCT07046585 | Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC) | Not listed | Recruiting | May 30, 2025 | Jul 10, 2027 (estimated) |
| NCT05170425 | LAMBDA 002 (Lung Registry) Study | Not listed | Active, not recruiting | Nov 4, 2022 | 2026-08 (estimated) |
| NCT05205551 | Prospera Test Evaluation in Cardiac Transplant (ProTECT) | Not listed | Active, not recruiting | Oct 1, 2021 | Oct 31, 2026 (estimated) |
| NCT03984747 | Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection | Not listed | Completed | Sep 14, 2018 | Aug 23, 2024 (actual) |
| NCT06620627 | Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection | Not listed | Recruiting | Jan 26, 2024 | Jul 31, 2025 (estimated) |
| NCT05309382 | Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation | Not listed | Completed | Dec 12, 2022 | Oct 2, 2024 (actual) |
| NCT05312814 | Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Management. | Not listed | Completed | Oct 1, 2021 | May 15, 2023 (actual) |
| NCT04761783 | BESPOKE Study of ctDNA Guided Immunotherapy | Not listed | Completed | May 28, 2021 | Dec 31, 2023 (actual) |
| NCT04091984 | The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive) | Not listed | Active, not recruiting | Nov 6, 2019 | Oct 1, 2026 (estimated) |
| NCT05081739 | Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation | Not phased (device or behavioral study) | Withdrawn | 2023-01 | 2025-01 (estimated) |
| NCT04264702 | BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer | Not listed | Unknown status (ClinicalTrials.gov) | Apr 24, 2020 | 2025-09 (estimated) |
| NCT05846113 | Renasight Clinical Application, Review and Evaluation (RenaCARE) Study | Not phased (device or behavioral study) | Unknown status (ClinicalTrials.gov) | Jun 7, 2021 | 2025-08 (estimated) |
| NCT01545674 | Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial | Not listed | Terminated | 2012-01 | 2014-04 (actual) |
| NCT02381457 | SNP-based Microdeletion and Aneuploidy RegisTry (SMART) | Not listed | Completed | 2015-04 | 2020-06 (actual) |
| NCT01852708 | Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood | Not listed | Completed | 2012-11 | 2020-10 (actual) |
| NCT03485651 | Natera Ovarian Cancer Detection Assay | Not listed | Terminated | Dec 14, 2017 | Nov 1, 2019 (actual) |
| NCT02278536 | Multiple Gestation Study | Not listed | Completed | 2013-03 | 2019-03 (actual) |
| NCT02109770 | Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA | Not listed | Completed | 2012-10 | 2019-06 (actual) |
| NCT02278874 | High Risk Multiple Gestation Study | Not listed | Completed | 2014-08 | Dec 1, 2018 (actual) |
| NCT01194531 | Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplantation Genetic Screening (PGS) With Day 5 Fresh Transfer | Phase 4 | Terminated | 2010-09 | 2013-04 (actual) |
| NCT01023048 | Concurrent Single Gene and 24 Chromosome Aneuploidy Preimplantation Genetic Diagnosis (PGD) | Not phased (device or behavioral study) | Completed | 2009-11 | 2014-03 (actual) |
| NCT01546324 | Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing | Not listed | Completed | 2012-02 | 2012-05 (actual) |
| NCT01663584 | Multi-disease Carrier Screening Test Validation | Not listed | Withdrawn | 2012-08 | 2013-06 (actual) |
| NCT01197872 | Clinical Use of Parental Support To Detect Single Gene Mutations | Not listed | Completed | 2010-09 | 2013-06 (actual) |
| NCT01574781 | Non-invasive Prenatal Diagnostic Validation Study | Not listed | Completed | 2011-09 | 2013-04 (actual) |
NIH awards 11
- NIH award 5R44HD062114-03 FY2012: $802,079 awarded for that fiscal year; activity R44 (SBIR); PI RABINOWITZ, MATTHEW; recipient as written: NATERA, INC., SAN CARLOS, CA. Non-invasive Aneuploidy Screening of Circulati source ↗
- NIH award 4R44HD062114-02 FY2011: $800,745 awarded for that fiscal year; activity R44 (SBIR); PI RABINOWITZ, MATTHEW; recipient as written: NATERA, INC., SAN CARLOS, CA. Non-invasive Aneuploidy Screening of Circulati source ↗
- NIH award 5R44HD060423-03 FY2010: $799,036 awarded for that fiscal year; activity R44 (SBIR); PI RABINOWITZ, MATTHEW; recipient as written: NATERA, INC., SAN CARLOS, CA. Array informatics to understand ploidy concord source ↗
- NIH award 1R44HD062114-01A1 FY2010: $200,833 awarded for that fiscal year; activity R44 (SBIR); PI RABINOWITZ, MATTHEW; recipient as written: NATERA, INC., SAN CARLOS, CA. Non-invasive Aneuploidy Screening of Circula source ↗
- NIH award 4R44HD060423-02 FY2009: $800,710 awarded for that fiscal year; activity R44 (SBIR); PI RABINOWITZ, MATTHEW; recipient as written: NATERA, INC., SAN CARLOS, CA. Array informatics to understand ploidy concord source ↗
- NIH award 5R44HD054958-03 FY2009: $658,668 awarded for that fiscal year; activity R44 (SBIR); PI RABINOWITZ, MATTHEW; recipient as written: NATERA, INC., SAN CARLOS, CA. Novel Informatics for Highly Reliable Multi-Lo source ↗
- NIH award 1R44HD060423-01 FY2009: $200,068 awarded for that fiscal year; activity R44 (SBIR); PI RABINOWITZ, MATTHEW; recipient as written: NATERA, INC., SAN CARLOS, CA. Array informatics to understand ploidy concord source ↗
- NIH award 2R44HD054958-02A2 FY2008: $835,485 awarded for that fiscal year; activity R44 (SBIR); PI RABINOWITZ, MATTHEW; recipient as written: NATERA, INC., SAN CARLOS, CA. Novel Informatics for Highly Reliable Multi- source ↗
- NIH award 1R43HD054958-01A1 FY2007: $195,749 awarded for that fiscal year; activity R43 (SBIR); PI RABINOWITZ, MATTHEW; recipient as written: NATERA, INC., SAN CARLOS, CA. Phase I Application: Cleaning of Single Cell source ↗
- NIH award 1R43AI070057-01A1 FY2006: $178,940 awarded for that fiscal year; activity R43 (SBIR); PI RABINOWITZ, MATTHEW; recipient as written: NATERA, INC., SAN CARLOS, CA. Novel Statistical Methods for Improving the source ↗
- NIH award 1R43GM077682-01 FY2006: $218,859 awarded for that fiscal year; activity R43 (SBIR); PI RABINOWITZ, MATTHEW; recipient as written: NATERA, INC., SAN CARLOS, CA. Integrating, Validating & Applying Pharmacogen source ↗
Raises and investors new
- InvestorListed in the portfolio of Sofinnova Investments (captured Oct 12, 2026). portfolio page ↗
- InvestorListed in the portfolio of Bain Capital Life Sciences (captured Oct 12, 2026). portfolio page ↗
Connect
See your connections at Natera on LinkedIn (search by name, results not checked)